Since our inception in 1990, we’ve strived to work as a ‘trusted partner’ to our clients, collaborating, innovating and finding new ways to improve outcomes.

ICON has worked with and developed strategic partnerships with many of the world’s largest pharma companies. And every partnership into which ICON has entered is still ongoing and evolving with our clients’ needs. We’ve built our reputation on enduring partnerships that advance medicine and make a difference in the world. 

Our award-winning study execution capabilities have led to the approval of 18 of the world’s top 20 best-selling drugs.

Integrated delivery model

Our partnership models integrate our own multidisciplinary expertise with that of our clients, for more efficient trial design, more effective utilisation of digital technologies and real world data, and optimal patient recruitment and engagement.

Therapeutic and operational expertise

We focus on the factors that are critical to our clients – accelerating time to market, reducing cost and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.

Our functional and therapeutic expertise includes inflammation, dermatology, cardio-metabolic, oncology/haematology, infectious diseases, neurology/psychiatryrare disease, respiratory, and biosimilars

Expanded access to sites and patients

ICON provides enhanced access to patients and multi-specialty physicians through our Accellacare site network, specialised Oncacare sites, EU and US phase 1 units, and in-home services.